Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flurandrenolide is a synthetic fluorinated corticosteroid used topically for its anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts as an agonist at the glucocorticoid receptor, leading to the induction of phospholipase A2 inhibitory proteins, known as lipocortins. These proteins control the biosynthesis of potent mediators of inflammation, such as prostaglandins and leukotrienes, by inhibiting the release of their common precursor, arachidonic acid. Flurandrenolide is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, including eczematous dermatitis, psoriasis, and various forms of dermatitis. Originally developed by Eli Lilly under the brand name Cordran, it is available in several formulations including ointments, creams, lotions, and a unique medicated tape for sustained topical delivery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on flurandrenolide.